BR0211932A - Métodos e composições para administração oral de hormÈnio de paratireóide, pth - Google Patents

Métodos e composições para administração oral de hormÈnio de paratireóide, pth

Info

Publication number
BR0211932A
BR0211932A BR0211932-3A BR0211932A BR0211932A BR 0211932 A BR0211932 A BR 0211932A BR 0211932 A BR0211932 A BR 0211932A BR 0211932 A BR0211932 A BR 0211932A
Authority
BR
Brazil
Prior art keywords
methods
compositions
pth
parathyroid hormone
oral administration
Prior art date
Application number
BR0211932-3A
Other languages
English (en)
Other versions
BRPI0211932B1 (pt
Inventor
Moise Azria
Simon David Bateman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0211932A publication Critical patent/BR0211932A/pt
Publication of BRPI0211932B1 publication Critical patent/BRPI0211932B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODOS E COMPOSIçõES PARA ADMINISTRAçãO ORAL DE HORMÈNIO DE PARATIREóIDE, PTH". Composições farmacêuticas para a efetiva liberação oral de um hormónio de paratireóide, PTH, assim como métodos para administração das composições são providos. Adicionalmente, métodos para estimulação de nova formação de ossos e tratamento e/ou prevenção de osteoporose também são providos.
BRPI0211932A 2001-08-17 2002-08-16 composição farmacêutica na forma de dosagem sólida para liberação oral, e uso de sal dissódio de ácido n-(5-cloro-saliciloil)-8-aminocaprílico (5-cnac) BRPI0211932B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31304801P 2001-08-17 2001-08-17
PCT/EP2002/009181 WO2003015822A1 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (2)

Publication Number Publication Date
BR0211932A true BR0211932A (pt) 2004-10-26
BRPI0211932B1 BRPI0211932B1 (pt) 2016-12-06

Family

ID=23214149

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0211932A BRPI0211932B1 (pt) 2001-08-17 2002-08-16 composição farmacêutica na forma de dosagem sólida para liberação oral, e uso de sal dissódio de ácido n-(5-cloro-saliciloil)-8-aminocaprílico (5-cnac)

Country Status (26)

Country Link
US (4) US20040242478A1 (pt)
EP (1) EP1420827B8 (pt)
JP (2) JP4959917B2 (pt)
KR (1) KR20040030120A (pt)
CN (1) CN1279981C (pt)
AT (1) ATE443527T1 (pt)
AU (1) AU2002333443C1 (pt)
BR (1) BRPI0211932B1 (pt)
CA (1) CA2453646C (pt)
CO (1) CO5560586A2 (pt)
CY (1) CY1109661T1 (pt)
DE (1) DE60233803D1 (pt)
DK (1) DK1420827T3 (pt)
EC (1) ECSP044961A (pt)
ES (1) ES2333587T3 (pt)
HU (1) HUP0401441A3 (pt)
IL (2) IL159714A0 (pt)
MX (1) MXPA04001418A (pt)
NO (1) NO328069B1 (pt)
NZ (1) NZ531018A (pt)
PL (1) PL210258B1 (pt)
PT (1) PT1420827E (pt)
RU (1) RU2322256C2 (pt)
SI (1) SI1420827T1 (pt)
WO (1) WO2003015822A1 (pt)
ZA (1) ZA200400242B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040007617A (ko) * 2001-06-01 2004-01-24 노파르티스 아게 부갑상선 호르몬 및 칼시토닌의 경구 투여
CA2453646C (en) * 2001-08-17 2008-09-30 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
WO2003086408A1 (en) * 2002-04-10 2003-10-23 University Of Virginia Patent Foundation Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TWI343816B (en) 2003-07-23 2011-06-21 Novartis Ag Use of calcitonin in osteoarthritis
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
CA2607901C (en) * 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
AR058053A1 (es) 2005-09-19 2008-01-23 Toole Doris C O Formas cristalinas polimorficas de la sal de di- sodio del acido n- (5 -clorosaliciloil)-8- aminocaprilico
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
AU2006315132A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
EP2059260B1 (en) * 2006-08-31 2013-06-19 Novartis AG Pharmaceutical compositions comprising hGH for oral delivery
CA2679782C (en) 2007-03-02 2015-02-17 Novartis Ag Oral administration of a calcitonin
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
US20180050096A1 (en) * 2015-02-09 2018-02-22 Entera Bio Ltd. Treatment of hypoparathyroidism
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
CZ286632B6 (cs) * 1992-09-29 2000-05-17 Inhale Therapeutic Systems Farmaceutický prostředek
ATE383169T1 (de) * 1997-02-07 2008-01-15 Emisphere Tech Inc Komponente und zusammensetzungen zur verabreichung von wirkstoffen
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1175444B1 (en) * 1998-11-25 2008-01-23 The General Hospital Corporation Amino-terminal modified parathyroid hormone (pth) analogs
ATE288415T1 (de) * 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
CA2402719C (en) * 2000-03-21 2012-03-20 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
KR20040007617A (ko) * 2001-06-01 2004-01-24 노파르티스 아게 부갑상선 호르몬 및 칼시토닌의 경구 투여
CA2453646C (en) * 2001-08-17 2008-09-30 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
BRPI0412458A (pt) * 2003-07-11 2006-10-17 Novartis Ag composições farmacêuticas oralmente dosadas compreendendo um agente de liberação na forma micronizada

Also Published As

Publication number Publication date
CA2453646C (en) 2008-09-30
BRPI0211932B1 (pt) 2016-12-06
KR20040030120A (ko) 2004-04-08
US20060217313A1 (en) 2006-09-28
NO20040598L (no) 2004-02-10
US9272040B2 (en) 2016-03-01
CA2453646A1 (en) 2003-02-27
PT1420827E (pt) 2009-12-15
CO5560586A2 (es) 2005-09-30
PL210258B1 (pl) 2011-12-30
CY1109661T1 (el) 2014-08-13
AU2002333443B2 (en) 2006-06-29
AU2002333443C1 (en) 2009-10-08
RU2322256C2 (ru) 2008-04-20
JP4959917B2 (ja) 2012-06-27
JP2009242410A (ja) 2009-10-22
CN1543357A (zh) 2004-11-03
US20120088725A1 (en) 2012-04-12
EP1420827B8 (en) 2009-12-23
RU2004107899A (ru) 2005-05-10
ECSP044961A (es) 2004-03-23
MXPA04001418A (es) 2004-05-27
WO2003015822A1 (en) 2003-02-27
HUP0401441A2 (hu) 2004-12-28
DE60233803D1 (de) 2009-11-05
EP1420827B1 (en) 2009-09-23
US20040242478A1 (en) 2004-12-02
ATE443527T1 (de) 2009-10-15
IL159714A (en) 2010-12-30
US20090264367A1 (en) 2009-10-22
CN1279981C (zh) 2006-10-18
PL365388A1 (en) 2005-01-10
EP1420827A1 (en) 2004-05-26
HUP0401441A3 (en) 2012-09-28
NZ531018A (en) 2006-03-31
SI1420827T1 (sl) 2010-01-29
ES2333587T3 (es) 2010-02-24
DK1420827T3 (da) 2009-12-21
NO328069B1 (no) 2009-11-23
JP2005501852A (ja) 2005-01-20
IL159714A0 (en) 2004-06-20
ZA200400242B (en) 2004-11-18

Similar Documents

Publication Publication Date Title
BR0211932A (pt) Métodos e composições para administração oral de hormÈnio de paratireóide, pth
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
UY26130A1 (es) Compuestos para tratar la obesidad
GT199700009AA (es) Terapia combinada para la osteoporosis
ATE500218T1 (de) Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
BR0309875A (pt) métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
SE0100568D0 (sv) Compounds
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
HK1078466A1 (en) Treatment of affective disorders by the combined action of a nicotinic ; receptor agonist and a monoaminergic substance
BR0309278A (pt) Composto, composição, métodos para modular a atividade da cinesina ksp, para inibir a ksp, para o tratamento de uma doença proliferativa celular, e, uso de um composto
PT998287E (pt) Utilizacao de levobupivacaina
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
SE0100566D0 (sv) Compounds
CO5540323A2 (es) Administracion oral de hormona paratiroides y calcitonina
PE20000644A1 (es) Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
BR9814867A (pt) Método para tratar discinesias relacionadas a doenças ou induzidas por drogas
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
SE0101692D0 (sv) Compounds
BR0209892A (pt) Método de preparação de um composto, composto, composição farmacêutica, uso de um composto, e, método de tratamento de um paciente sofrendo de uma doença ou condição mediada por hppar alfa
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
AU2002319223A1 (en) Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/12/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.